Alnylam Pharmaceuticals Inc. (ALNY)

73.02
1.52 2.13
NASDAQ : Health Technology
Prev Close 71.50
Open 72.54
Day Low/High 71.94 / 74.34
52 Wk Low/High 60.27 / 124.22
Volume 863.43K
Avg Volume 957.10K
Exchange NASDAQ
Shares Outstanding 106.54M
Market Cap 7.46B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Strong On High Volume: Alnylam Pharmaceuticals (ALNY)

Strong On High Volume: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a strong on high relative volume candidate

Insiders Now Seeing Red With ALNY At New 52-Week Low

Insiders Now Seeing Red With ALNY At New 52-Week Low

In trading on Thursday, shares of Alnylam Pharmaceuticals Inc touched a new 52-week low of $49.96/share. That's a $90.04 share price drop, or -64.31% decline from the 52-week high of $140.00 set back on 06/23/2015.

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2016, and highlighted recent progress in advancing its pipeline.

Alnylam Manufacturing Facility To Be Built In Norton, Massachusetts. (Photo: Business Wire)

Alnylam Manufacturing Facility To Be Built In Norton, Massachusetts. (Photo: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will break ground today on a state-of-the-art biopharmaceutical manufacturing facility in Norton,...

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Deutsche Bank 41 st Annual Health Care Conference on...

Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2016 on Monday, May 2, 2016, after the...

Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)

Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today complete 18-month data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi...

Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today

Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 15 th Annual Needham Healthcare Conference on Wednesday,...

Somber Sentiment Makes Me Wonder

I still see an April correction and then a rally, but sentiment is a worry.

Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study

Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has initiated dosing of hemophilia patients with inhibitors in Part D of an ongoing Phase 1 clinical trial...

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Here are Friday's top research calls, including upgrades for Chevron, Hertz and Kohl's, and a downgrade for Blackstone.

3 Stocks Pulling The Drugs Industry Downward

3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-GO1, a subcutaneously administered investigational RNAi...

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 36 th Annual Healthcare Conference on...

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2015, and highlighted recent progress on its...

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2015 on Thursday, February...

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the 18 th Annual BIO CEO & Investor Conference on Tuesday,...

Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has completed enrollment - with well over 200 patients accrued - in its APOLLO Phase 3 study with patisiran,...

Weak On High Volume: Alnylam Pharmaceuticals (ALNY)

Weak On High Volume: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock

Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline

Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today its pipeline goals for 2016 across its Genetic Medicine, Cardio-Metabolic Disease, and Hepatic Infectious Disease...

Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 34 th Annual J.

Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference

Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs "Healthcare CEOs Unscripted: A View from the...

Sell These 6 Biotech Stocks Now Before It's Too Late

Sell These 6 Biotech Stocks Now Before It's Too Late

Biotech stocks are set to outperform in 2015, but here are six stocks that investors should steer clear of in 2016.

Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has filed a Clinical Trial Application (CTA) with the U.

Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage

Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Michael Bonney, current Board member and former chief executive of Cubist Pharmaceuticals, has been appointed as...